Prevention of mother-to-child transmission of HIV

Clinical Obstetrics and Gynecology

Volumn 44, Issue 2, 2001, Pages 210-225

  Minkoff, Howard ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

CESAREAN SECTION; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL CARE; MOTHER CHILD RELATION; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRENATAL CARE; REVIEW; UNITED STATES; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CESAREAN SECTION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PERINATAL CARE; PREGNANCY; VIRAL LOAD; ZIDOVUDINE;

EID: 0035028549     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200106000-00010     Document Type: Review

References (69)

1. Antiretroviral therapy of the pregnant women
2. The efficacy of ZDV in the treatment of patients with AIDS and AIDS-related complex. A double-blind placebo controlled trial
3. A randomized controlled trial of reduced daily dose of ZDV in patients with acquired immunodeficiency syndrome
4. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind placebo controlled trial
5. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference
6. A controlled trial of early versus late treatment with ZDV in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study
7. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred ZDV in symptom free HIV infection
8. Preclinical toxicology of zidovudine: An overview
9. Effect of zidovudine on preimplantation murine embryos
10. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection
11. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I ACTG study (protocol 082)
12. Pharmacokinetic disposition of zidovudine during pregnancy
13. Zidovudine therapy of HIV-1 infection during pregnancy: Assessment of the effect on the newborns
14. Factors predictive of maternal-fetal transmission of HIV-1: Preliminary analysis of zidovudine (ZDV) given during pregnancy and/or delivery
15. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
16. Can perinatal HIV infection be eliminated in the United States?
17. After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants
18. Abbreviated regiments of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
19. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune globulin for reducing perinatal HIV transmission from Women infected with HIV with advanced disease: Results of Pediatric AIDS Clinical Trials Group protocol 185
20. Trends in human immunodeficiency virus (HIV) counseling, testing and antiretroviral treatment of Women infected with HIV and perinatal transmission in North Carolina
21. Efficacy of zidovudine and HIV hyperimmune immunoglobulin for reducing perinatal HIV transmission from Women infected with HIV with advanced disease: Results of pediatric clinical AIDS Trials Group Protocol 185
22. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine
23. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to Women infected with HIV
24. Birth outcomes following zidovudine therapy in pregnant women
25. Transplacental effects of 3′-azido-2′3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys
26. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus
27. Therapy for human immunodeficiency virus infection
28. Long-term persistence of zidovudine resistance mutations in plasma isolates from human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy
29. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand 1996-1998
30. Six-month efficacy, tolerance, and acceptability of a short region of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo controlled multicenter trial
31. Short course oral zidovudine for prevention of mother-to-child transmision of HIV-1 in Abidjan, Cote d'Ivoire: A randomized trial
32. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
33. Intrapartum and neonatal single-dose nevirapine compared with zidovudine fro prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
34. The effect of mode of delivery and other variables on the early efficacy of three short ZDV/3tC combination regimens to prevent mother-to-child transmission of HIV-1: The PETRA Trial
35. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
36. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
37. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
38. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1,000 copies/mL
39. HIV vertical transmission rates according to antiretroviral therapy and viral load during pregnancy among 347 mother-child pairs 1998-1999 (PACTG 367)
40. Selection of the K103 nevirapine resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 006)
41. Ȧntiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS Society: USA Panel
42. Proposed definition for in utero versus intrapartum transmission of HIV-1
43. Usefulness and timing of blood culture in the first six months of life for the diagnosis of vertically transmitted HIV infection
44. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates
45. HIV replication during the first few weeks of life
46. PCR and HIV-IgA for early infant diagnosis of perinatal HIV infection
47. Conversion of HIV viral markers during the first months of life in HIV-infected children born to seropositive mothers
48. Identifying human immunodeficiency virus infection at birth: Application of polymerase chain reaction to Guthrie cards
49. The relationship of the duration of ruptured membranes to vertical transmission of HIV
50. The relationship of obstetrical factors to the mother-to-child transmission of HIV-1
51. Cesarean section to reduce perinatal transmission of human immunodeficiency virus: A meta-analysis
52. HIV and childbearing: Clinical outcome and aspects of mother-to-infant transmission
53. Epidemiology of vertically transmitted HIV infection in Switzerland: Results of a nationwide prospective study
54. Mother-to-child transmission of HIV 1: Risk of infection and correlates of transmission
55. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire
56. The influence of birth weight on labor in nulliparas
57. High risk of infection with human immunodeficiency virus type I for first-born vaginally delivered twins
58. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels
59. Infection with HIV as a risk factor for adverse obstetrical outcome
60. Impact of maternal HIV infection on obstetrical and early neonatal outcome
61. A prospective study of infants of human immunodeficiency virus seropositive and seronegative women with a history of intravenous drug use or of intravenous drug-using partners, in the Bronx, New York City
62. Perinatal transmission of HIV-1: Lack of impact of maternal HIV infection on characteristics of livebirths and on neonatal mortality in Kigali, Rwanda
63. Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort
64. Prevention of vertical HIV transmission: Additive protective effect of elective cesarean section and zidovudine prophylaxis
65. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A meta-analysis of 15 prospective cohort studies
66. Elective cesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial
67. Perinatal intervention trial in Africa: Effect of a birth canal cleansing intervention to prevent HIV transmission